2 Pharmaceutical Stocks to Buy at a Discount

With headlines dominated by GLP-1 weight‑loss drugs and Eli Lilly’s high valuation (P/E ~50 and >50% of revenue tied to two GLP‑1 products), the article highlights Merck and Bristol Myers Squibb as lower‑risk, value‑oriented alternatives: Merck trades at a P/E of ~13 (five‑year avg 21) with a 3.4% yield and ~45% payout ratio, while Bristol Myers Squibb trades at ~17.5 P/E with a 4.7% yield but a near‑85% payout ratio. Both firms focus on cardiovascular, oncology and immune/infectious disease franchises rather than GLP‑1s, offering dividend income and more attractive valuations versus the market darling, though investors should weigh BMY’s high payout and the sector’s patent‑cliff risks.

Analysis

GLP-1 weight‑loss drugs dominate headlines and have driven Eli Lilly's shares to a price‑to‑earnings ratio near 50, marginally below its five‑year average of 53, with more than 50% of Lilly's revenue coming from two GLP‑1 products — a concentration risk the article highlights. Such elevated valuation and revenue concentration contrast with other large-cap pharmas and underpin the author's caution about market myopia.

Merck and Bristol Myers Squibb are presented as lower‑priced alternatives: Merck trades at a P/E of about 13 (five‑year average 21) with a 3.4% yield focused on cardiovascular, oncology and infectious‑disease franchises, while BMY trades at ~17.5 P/E with a 4.7% yield and focuses on cardio, cancer and immune disorders. The dividend profiles differ materially — Merck's payout ratio is roughly 45% versus Bristol Myers Squibb's nearly 85% — implying stronger dividend sustainability at Merck.

The article frames both names as industry stalwarts trading at more attractive valuations than the GLP‑1 leader, but it also reminds readers of sector realities like patent cliffs and the ongoing need for new drugs. Readers should also note the disclosure that The Motley Fool holds positions in and recommends BMY and MRK, which may influence the recommendation tone.

Key Decisions for Investors

• Consider initiating or adding to Merck on valuation and dividend sustainability given its ~13 P/E and ~45% payout ratio,
• Consider Bristol Myers Squibb for higher income (4.7% yield) but size positions conservatively and monitor dividend coverage closely due to the nearly 85% payout ratio,
• Limit or hedge exposure to Eli Lilly at current valuations (P/E ~50 and >50% revenue tied to two GLP‑1 drugs) and track patent‑cliff and pipeline updates for all three names